PMC10460171_01
Psoriasis worsened (trunk).
PTT-13-27-g0001.jpg
PMC10460171_01_PTT-13-27-g0001.jpg
f0001
While BP improved rapidly with BPDAI 16, psoriasis worsened (Figures 1 and Figure 2).
Psoriasis worsened (lower limbs).
PTT-13-27-g0002.jpg
PMC10460171_01_PTT-13-27-g0002.jpg
f0002
While BP improved rapidly with BPDAI 16, psoriasis worsened (Figures 1 and Figure 2).
Clinical remission of both psoriatic e PB lesions on the trunk after DMF therapy.
PTT-13-27-g0003.jpg
PMC10460171_01_PTT-13-27-g0003.jpg
f0003
At his most recent follow-up visit, 12 months after the initiation of risankizumab therapy, no relapse of both diseases was seen (Figures 3 and Figure 4).    
Clinical remission on lower limbs.
PTT-13-27-g0004.jpg
PMC10460171_01_PTT-13-27-g0004.jpg
f0004
At his most recent follow-up visit, 12 months after the initiation of risankizumab therapy, no relapse of both diseases was seen (Figures 3 and Figure 4).    